NEW YORK, Nov. 13 - AlphaGene announced Tuesday that it had entered into an agreement with Celera Genomics, which will distribute AlphaGene's set of full-length human clones.
Celera will make this data available through its subscription database both to academic and commercial researchers.
By the terms of the agreement, AlphaGene will isolate known clones from public databases. Celera will map those clone sequences to its human genome database.
AlphaGene, a Woburn, Mass.-based functional genomics company, will also be responsible for sequencing and manufacturing the clones.
Financial terms of the agreement were not disclosed, although Celera will market the effort.
The company focuses on gene expression in degenerative neurological diseases like Parkinson's and Alzheimer's, and has constructed more than 200 cDNA libraries from major organs and tissues in the body. More than half of the gene inventory is derived from neurological tissue.